UNITED THERAPEUTICS (UTH BE) stock market data APIs
€407.8582
0.1(0%)
as of November 17, 2025
Try our APIs with
free plan!
UNITED THERAPEUTICS Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for UTH.BE.
Prev. Close
407.8582
Open
407.9543
High
409.7003
Low
399.5178
52 wk Range
237.2-407.6
Market Cap
7 520 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get UNITED THERAPEUTICS data using free add-ons & libraries
Get UNITED THERAPEUTICS Fundamental Data
UNITED THERAPEUTICS Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-29
- EPS/Forecast: 7.31
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
UNITED THERAPEUTICS News
New
3 Market-Beating Stocks Worth Your Attention
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legend...
Pulmonary Arterial Hypertension Market Research Report 2025, Competitive Analysis of Gilead Sciences, Viatris, Sandoz, J&J, Sun Pharma, Lupin Pharma, GlaxoSmithKline, Bayer, United Therapeutics
Company Logo Market opportunities in the Pulmonary Arterial Hypertension (PAH) sector include increased demand for innovative therapies due to rising PAH prevalence and greater awareness, alongside e...
3 Reasons Investors Love United Therapeutics (UTHR)
United Therapeutics has been on fire lately. In the past six months alone, the company’s stock price has rocketed 44.4%, reaching $448.91 per share. This performance may have investors wondering how...
How Investors May Respond To United Therapeutics (UTHR) Pioneering Successful Clinical Xenotransplantation for Kidney Patients
United Therapeutics recently announced the first successful clinical xenotransplantation of its UKidney™ in patients with end-stage renal disease, as part of the multicenter EXPAND study at NYU Lang...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
